» Articles » PMID: 25628933

Anti-miR21 Oligonucleotide Enhances Chemosensitivity of T98G Cell Line to Doxorubicin by Inducing Apoptosis

Abstract

Various signal transduction pathways seem to be involved in chemoresistance mechanism of glioblastomas (GBMs). miR-21 is an important oncogenic miRNA which modulates drug resistance of tumor cells. We analyzed the expression of 5 miRNAs, previously found to be dysregulated in high grade gliomas, in 9 pediatric (pGBM) and in 5 adult (aGBM) GBMs. miR-21 was over-expressed, with a significant difference between pGBMs and aGBMs represented by a 4 times lower degree of expression in the pediatric compared to the adult series (p = 0.001). Doxorubicin (Dox) seems to be an effective anti-glioma agent with high antitumor activity also against glioblastoma stem cells. We therefore evaluated the chemosensitivity to Dox in 3 GBM cell lines (A172, U87MG and T98G). Dox had a cytotoxic effect after 48 h of treatment in A172 and U87MG, while T98G cells were resistant. TUNEL assay verified that Dox induced apoptosis in A172 and U87MG but not in T98G. miR-21 showed a low basal expression in treated cells and was over-expressed in untreated cells. To validate the possible association of miR-21 with drug resistance of T98G cells, we transfected anti-miR-21 inhibitor into the cells. The expression level of miR-21 was significantly lower in T98G transfected cells (than in the parental control cells). Transfected cells showed a high apoptotic rate compared to control after Dox treatment by TUNEL assay, suggesting that combined Dox and miR-21 inhibitor therapy can sensitize GBM resistant cells to anthracyclines by enhancing apoptosis.

Citing Articles

Oxime Linked Doxorubicin Glycoconjugates Improve the Specific Targeting of Glioblastoma in High-Grade Glioma Therapy.

Iorio A, Lenci E, Marzano C, Bucaletti E, Tirinnanzi B, Casati G ACS Med Chem Lett. 2024; 15(11):1953-1960.

PMID: 39563793 PMC: 11571026. DOI: 10.1021/acsmedchemlett.4c00398.


Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view.

Meinag F, Fatahi M, Vahedian V, Maroufi N, Mosayyebi B, Ahmadi E Funct Integr Genomics. 2024; 24(5):150.

PMID: 39222264 DOI: 10.1007/s10142-024-01431-x.


From Molecular Mechanisms to Therapeutics: Understanding MicroRNA-21 in Cancer.

Rhim J, Baek W, Seo Y, Kim J Cells. 2022; 11(18).

PMID: 36139366 PMC: 9497241. DOI: 10.3390/cells11182791.


Functionalized gold nanostructures: promising gene delivery vehicles in cancer treatment.

Kumar S, Diwan A, Singh P, Gulati S, Choudhary D, Mongia A RSC Adv. 2022; 9(41):23894-23907.

PMID: 35530631 PMC: 9069781. DOI: 10.1039/c9ra03608c.


NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).

Zeng Z, Chen Y, Geng X, Zhang Y, Wen X, Yan Q Int J Oncol. 2022; 60(6).

PMID: 35506469 PMC: 9083885. DOI: 10.3892/ijo.2022.5366.


References
1.
Krichevsky A, King K, Donahue C, Khrapko K, Kosik K . A microRNA array reveals extensive regulation of microRNAs during brain development. RNA. 2003; 9(10):1274-81. PMC: 1370491. DOI: 10.1261/rna.5980303. View

2.
Li T, Li D, Sha J, Sun P, Huang Y . MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009; 383(3):280-5. DOI: 10.1016/j.bbrc.2009.03.077. View

3.
Lou Y, Yang X, Wang F, Cui Z, Huang Y . MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int J Mol Med. 2010; 26(6):819-27. DOI: 10.3892/ijmm_00000530. View

4.
Shiohama A, Sasaki T, Noda S, Minoshima S, Shimizu N . Molecular cloning and expression analysis of a novel gene DGCR8 located in the DiGeorge syndrome chromosomal region. Biochem Biophys Res Commun. 2003; 304(1):184-90. DOI: 10.1016/s0006-291x(03)00554-0. View

5.
Ohgaki H, Kleihues P . Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007; 170(5):1445-53. PMC: 1854940. DOI: 10.2353/ajpath.2007.070011. View